07:00 , Jul 1, 2002 |  BC Week In Review  |  Clinical News

MorphiDex: Phase III

In a double-blind U.S. Phase III study in 193 patients with chronic pain, MorphiDex failed to meet the primary endpoint of lower morphine use compared to immediate release morphine. ENDP acquired MorphiDex through its 2000...
07:00 , Jul 1, 2002 |  BioCentury  |  Finance

Ebb & Flow

The first regulatory setback isn't the knockout punch for Oxford GlycoSciences(LSE:OGS; OGSI), which fell 92.5p (24%) to 300p on Monday after receiving a non-approvable letter from the FDA for its Vevesca (OGT 918) to treat...
07:00 , Jun 24, 2002 |  BC Extra  |  Clinical News

Endo's MorphiDex fails Phase III

ENDP said its MorphiDex combination of morphine with dextromethorphan NMDA receptor antagonist failed to meet the primary endpoint of lower morphine use compared to immediate release morphine in a double-blind U.S. Phase III study of...
08:00 , Jan 17, 2002 |  BC Extra  |  Financial News

Endo drops on Morphidex news

ENDP was off $2.34 (18%) to $10.56 on Thursday. The company announced after market close on Wednesday that it is experiencing slower than anticipated patient enrollment in clinical studies of its Morphidex combination of morphine...
07:00 , May 7, 2001 |  BioCentury  |  Finance

Measuring neuro progress

Measuring neuro progress Company IPO Status Algos (ALGO) $49.0M Merged with Endo (ENDP) in Dec. '99 after receiving a non-approvable letter from the FDA in Aug. '99 for MorphiDex (combination of morphine opioid analgesic...
07:00 , Oct 2, 2000 |  BC Week In Review  |  Clinical News

MorphiDex: Began Phase III trial

(Board, Management, B8) Endo Pharmaceuticals Holdings Inc. (ENDP), Chadds Ford, Penn.   Product: MorphiDex   Business: Neurological   Therapeutic category: Analgesic, Receptor antagonist   Target: NMDA and mu opioid receptors   Description: Combination of morphine with dextromethorphan NMDA receptor...
07:00 , Oct 2, 2000 |  BioCentury  |  Finance

Bio-equity sizzles

All was well in biotech last week, even as the tech-heavy NASDAQ Composite shed 3 percent. The BioCentury 100 traded up 2 percent, while $856.3 million was raised in six underwritten deals that included a...
07:00 , Sep 27, 2000 |  BC Extra  |  Top Story

FDA requests second trial from Endo

During a Sept. 25 meeting, the FDA requested a second pivotal chronic multiple dosing study of ENDP's MorphiDex opioid analgesic in addition to a pivotal study previously submitted to the agency. The company said the...
07:00 , Jul 24, 2000 |  BC Week In Review  |  Company News

Algos, Endo deal

The companies completed their previously announced merger (see BioCentury, Dec. 6, 1999). The combined company will be named Endo Pharmaceuticals Holdings Inc. and will trade on NASDAQ under the ticker ENDP. Algos Pharmaceutical Corp. (ALGO),...
07:00 , May 30, 2000 |  BC Week In Review  |  Company News

Medarex management update

Medarex Inc. (MEDX), Princeton, N.J.   Business: Cancer, Drug discovery   Hired: W. Bradford Middlekauff as VP and general counsel, formerly VP of business development and general counsel at Algos Pharmaceutical Corp.   ...